15 Results for 'Adeno-Associated Virus (AAV)'
MRBL: Next-Generation Gene Therapy for Molecular Skin Rejuvenation
The next-generation gene therapy for molecular skin rejuvenation combines a comprehensive target gene prediction with a novel transdermal delivery approach for therapeutic adenovirus-associated viruses. The platform targets monogenic disease indications in the skin, and extends the same targets to the treatment of common skin aging conditions.
Synthetic AAV Capsids for Advanced Gene Therapy
The protein shell (capsid) of Adeno-associated viruses (AAV) are presently the most promising delivery vehicles for various in vivo gene therapies. AAVs are non-pathogenic and, through past engineering efforts, have become safe due to their inability to integrate into and damage the genome of target cells. Rather, the delivered DNA containing a therapeutic gene of...
Video/AnimationImproving Canine HealthspanA Wyss Institute technology that can treat multiple age-related diseases is now being developed by Rejuvenate Bio into a treatment for mitral valve disease and other deadly conditions in dogs, with the goal of helping man’s best friend live longer, healthier lives. Credit: Wyss Institute at Harvard University
Video/AnimationAAV Capsid EngineeringWyss researchers have created a high-throughput platform to generate an Adeno-associated virus 2 (AAV2) library containing 200,000 variants, each carrying a distinct mutation in the virus capsid protein. Their analysis identified capsid changes that enhanced “homing” potential to specific organs in mice and virus viability, as well as a new protein hidden in the capsid-encoding...
May 16 → 19, 2018
- Add to Calendar
- Google Calendar
Wyss Core Faculty member George Church and Wyss team members Eric Kelsic, Kai Chan and Pierce Ogden will speak about their work on AAV capsid engineering as part of this year’s American Society of Gene and Cell Therapy Annual Meeting. Please visit the ASGCT Annual Meeting website, for more information related to the meeting and...